---
figid: PMC9614140__fonc-12-849352-g001
figtitle: 'PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From
  bench to bed'
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC9614140
filename: fonc-12-849352-g001.jpg
figlink: /pmc/articles/PMC9614140/figure/f1/
number: F1
caption: Mechanisms of PD-1/PD-L1 in the tumor microenvironment. Besides the first
  and second activation pathway between tumor cell and T cell, the T cell would be
  anergy when the PD-L1 combines with PD-1. While the T cell could be reactivated
  whether a PD-1 antibody or PD-L1 antibody combines with the receptor on T cell or
  tumor cell, respectively. The PD-1 antibody is referred to pembrolizumab, nivolumab,
  toripalimab, camrelizumab, et al., and the PD-L1 antibody is referred to atezolizumab,
  durvalumab, et al. TCR, T cell receptor; MHC, major histocompatibility complex;
  PD-1, programmed death receptor-1; PD-L1, programmed death ligand-1; Ab, antibody.
papertitle: 'PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From
  bench to bed.'
reftext: Weijia Huang, et al. Front Oncol. 2022;12:849352.
year: '2022'
doi: 10.3389/fonc.2022.849352
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.
keywords: cervical cancer | tumor microenvironment | PD-1 | PD-L1 | immune checkpoint
  inhibitor
automl_pathway: 0.8660333
figid_alias: PMC9614140__F1
figtype: Figure
redirect_from: /figures/PMC9614140__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9614140__fonc-12-849352-g001.html
  '@type': Dataset
  description: Mechanisms of PD-1/PD-L1 in the tumor microenvironment. Besides the
    first and second activation pathway between tumor cell and T cell, the T cell
    would be anergy when the PD-L1 combines with PD-1. While the T cell could be reactivated
    whether a PD-1 antibody or PD-L1 antibody combines with the receptor on T cell
    or tumor cell, respectively. The PD-1 antibody is referred to pembrolizumab, nivolumab,
    toripalimab, camrelizumab, et al., and the PD-L1 antibody is referred to atezolizumab,
    durvalumab, et al. TCR, T cell receptor; MHC, major histocompatibility complex;
    PD-1, programmed death receptor-1; PD-L1, programmed death ligand-1; Ab, antibody.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tcr
  - Mhc
  - zip
  - ab
  - Appl
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - HLA-C
  - CD28
  - CD86
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - APP
  - SUCLA2
  - CD274
---
